Identification of beta-arrestin-1 as a diagnostic biomarker in lung cancer.

ABSTRACT:

Background

Distinguishing lung adenocarcinoma (ADC) from squamous cell carcinoma (SCC) has a tremendous therapeutic implication. Sometimes, the commonly used immunohistochemistry (IHC) markers fail to discriminate between them, urging for the identification of new diagnostic biomarkers.

Methods

We performed IHC on tissue microarrays from two cohorts of lung cancer patients to analyse the expression of beta-arrestin-1, beta-arrestin-2 and clinically used diagnostic markers in ADC and SCC samples. Logistic regression models were applied for tumour subtype prediction. Parallel reaction monitoring (PRM)-based mass spectrometry was used to quantify beta-arrestin-1 in plasma from cancer patients and healthy donors.

Results

Beta-arrestin-1 expression was significantly higher

SUBMITTER: El-Khoury V 

PROVIDER: S-EPMC6162208 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature